Health

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…

6 months ago

The Ninth Circuit Orders California to Respond concerning its Mandatory DEI Indoctrination in Continuing Medical Education Courses, According to the Association of American Physicians and Surgeons

TUCSON, Ariz., Sept. 04, 2025 (GLOBE NEWSWIRE) -- On September 2, the U.S. Court of Appeals for the Ninth Circuit…

6 months ago

Avania Strengthens Leadership Team with Appointment of Four New Executives

BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania, the leading global MedTech advisory and clinical development partner,…

6 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical…

6 months ago

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

September 03, 2025 17:17 ET  | Source: Senseonics Holdings, Inc. CGM commercial operations to transition from Ascensia Diabetes Care to…

7 months ago

Sotera Health Announces Secondary Offering of Common Stock

September 03, 2025 16:57 ET  | Source: Sotera Health Services, LLC CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health…

7 months ago

UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences

September 03, 2025 16:57 ET  | Source: vTv Therapeutics Inc. HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv…

7 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

7 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

7 months ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025 17:00 ET  | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…

7 months ago
Show more Posts
Show previous Posts